PVRL2, a novel immune checkpoint, may inhibit PD-L1-T cell activity in various tumors, such as endometrial carcinoma, lung cancer, ovarian cancer and breast cancer (Whelan et al., 2019). Here, NECTIN2 is linked to lung carcinoma.